產(chǎn)品詳情
簡單介紹：
重組人類腫瘤壞死因子-α/ TNFSF2，變體蛋白與其它公司提供的重組蛋白不同，rHuTNF-α/TNFSF2, Variant蛋白產(chǎn)品為采用CFS的無細(xì)胞麥胚蛋白合成系統(tǒng)表達(dá)出來的重組蛋白，可表達(dá)出對細(xì)胞有毒性、易被蛋白酶降解的蛋白；并獲得具有良好的可溶性，并有翻譯后修飾、從而部分具有功能的蛋白.同時(shí)獨(dú)有的全自動(dòng)蛋白純化技術(shù)則簡便高效，將蛋白純化過程中對蛋白的損傷降低到*小程度.重組人類腫瘤壞死因子-α/ TNFSF2，變體蛋白（全長序列）產(chǎn)品可用于Western Blot驗(yàn)證、抗體制備、蛋白檢測、ELISA等試驗(yàn)中.
詳情介紹：
重組人類腫瘤壞死因子-α/ TNFSF2，變體蛋白
| Synonyms | Tumor Necrosis Factor, TNFSF2, Cachectin, Differentiation-inducing factor (DIF), Necrosin, Cytotoxin |
| Species | Human |
| Accession | P01375 |
| GeneID | 7124 |
| Source | Escherichia coli. |
| Molecular Weight | 重組人類腫瘤壞死因子-α/ TNFSF2，變體蛋白Approximately 16.9 kDa, a single non-glycosylated polypeptide chain containing 151 amino acids. Compared with the wild-type, rHuTNF-α Variant has an amino acid sequence (a.a.) deletion from a.a. 1-7, and the following a.a. substitutes Arg8, Lys9, Arg10 and Phe157 which is proven to have more activity and with less inflammatory side effect in vivo. |
| Quantity | 10μg/50μg/1000μg |
| AA Sequence | MRKRKPVAHV VANPQAEGQL QWLNRRANAL LANGVELRDN QLVVPSEGLY LIYSQVLFKG QGCPSTHVLL THTISRIAVS YQTKVNLLSA IKSPCQRETP EGAEAKPWYE PIYLGGVFQL EKGDRLSAEI NRPDYLDFAE SGQVYFGIIA F |
| Purity | > 98 % by SDS-PAGE and HPLC analyses. |
| Biological Activity | 重組人類腫瘤壞死因子-α/ TNFSF2，變體蛋白Fully biologically active when compared to standard. The ED50 as determined by a cytotoxicity assay using murine L929 cells is less than 0.01 ng/ml, corresponding to a specific activity of > 1.0 × 107 IU/mg in the presence of actinomycin D. |
| Physical Appearance | Sterile Filtered White lyophilized (freeze-dried) powder. |
| Formulation | Lyophilized from a 0.2 μm filtered concentrated solution in PBS, pH 7.0. |
| Endotoxin | Less than 1 EU/μg of rHu TNF-α/TNFSF2, Variant as determined by LAL method. |
| Reconstitution | 重組人類腫瘤壞死因子-α/ TNFSF2，變體蛋白We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1 % BSA to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at ≤ -20 °C. Further dilutions should be made in appropriate buffered solutions. |
| Storage | This lyophilized preparation is stable at 2-8 °C, but should be kept at -20 °C for long term storage, preferably desiccated. Upon reconstitution, the preparation is stable for up to one week at 2-8 °C. For maximal stability, apportion the reconstituted preparation into working aliquots and store at -20 °C to -70 °C. Avoid repeated freeze/thaw cycles. |
| 重組人類腫瘤壞死因子-α/ TNFSF2，變體蛋白 | |
| SDS-PAGE |
|
| Reference |
1. Davenport C, Kenny H, Ashley DT, et al. 2012. Eur J Clin Invest, 42: 1173-9. 2. Cavalcanti YV, Brelaz MC, Neves JK, et al. 2012. Pulm Med, 2012: 745483. 3. Sheng WS, Hu S, Ni HT, et al. 2005. J Leukoc Biol, 78: 1233-41. 4. Berthold-Losleben MandHimmerich H. 2008. Curr Neuropharmacol, 6: 193-202. |
| Background | The clinical use of the potent antitumor activity of TNF-αhas been limited by the proinflammatory side effects including fever, dose-limiting hypotension, hepatotoxicity, intravascular thrombosis, and hemorrhage. Designing clinically applicable TNF-αmutants with low systemic toxicity has been an intense pharmacological interest. Human TNF-α, which binds to the murine TNF-R55 but not to the murine TNF-R75, exhibits retained antitumor activity and reduced systemic toxicity in mice compared with murine TNF-α, which binds to both murine TNF receptors. Based on these results, many TNF-αmutants that selectively bind to TNF-R55 have been designed. These mutants displayed cytotoxic activities on tumor cell lines in vitro, and exhibited lower systemic toxicity in vivo. |
